Healthcare Services

Endotoxin testing market outlook (2026–2030)

April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Endotoxin Testing Market During The Forecast Period?

The endotoxin testing market size has witnessed substantial growth in recent years. It is projected to expand from $2.31 billion in 2025 to $2.44 billion in 2026, registering a compound annual growth rate (CAGR) of 5.5%. The expansion observed in the historic period was primarily driven by drug safety regulations, growth in pharmaceutical manufacturing, medical device quality standards, patient safety concerns, and laboratory testing expansion.

The endotoxin testing market is projected to experience robust expansion over the coming years. By 2030, its value is anticipated to reach $3.12 billion, advancing at a compound annual growth rate (CAGR) of 6.3%. This expansion during the forecast period is driven by factors such as the rise of biologic drugs, more stringent regulatory scrutiny, increased automation in quality assessments, advancements in medical devices, and improved management of contamination risks. Key trends anticipated for this period encompass a heightened emphasis on pharmaceutical safety, more demanding regulatory compliance standards, an increase in quality testing for medical devices, the broader adoption of in vitro diagnostic testing, and a need for precise endotoxin detection.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/endotoxin-testing-global-market-report

What Major Factors Are Driving The Endotoxin Testing Market Forward?

The escalating frequency of healthcare-associated infections (HAIs) is anticipated to drive the expansion of the endotoxin testing market. These infections are defined as those acquired during medical care that were not present upon hospital admission. Factors contributing to the rise in HAIs include inadequate infection prevention and control practices, exposure to contaminated medical devices, and the growing prevalence of drug-resistant pathogens. Endotoxin testing significantly enhances patient safety by identifying bacterial endotoxins in medical equipment, injectable pharmaceuticals, and implantable devices, thereby mitigating the risk of sepsis, inflammation, and device-related complications. For example, in November 2024, the World Health Organization (WHO), a Switzerland-based public health agency, reported in its Global Report on Infection Prevention and Control 2024 that while 71% of countries possess active IPC programmes, merely 6% met all WHO minimum IPC requirements in 2023–2024, exposing millions of patients to a heightened risk of HAIs. Thus, the increasing incidence of healthcare-associated infections is a key driver for the growth of the endotoxin testing market.

What Are The Main Segments Within The Endotoxin Testing Market Segment Structure?

The endotoxin testing market covered in this report is segmented –

1) By Test Type: LAL (Limulus Amebocyte Lysate) Test, Chromogenic Tests, Turbidimetric Tests, Gel Clot Tests, MAT Test, Rabbit Pyrogen Test, Recombinant Factor C (rFC) Assay

2) By Application: Medical Devices, Pharmaceuticals, Packaging, Raw Materials

3) By End-User: Hospitals, Laboratories, Research Institutes

Subsegments:

1) By LAL (Limulus Amebocyte Lysate) Test: Gel Clot LAL Test, Kinetic LAL Test, Endpoint LAL Test

2) By Chromogenic Tests: Chromogenic LAL Test, Chromogenic Factor C Assay

3) By Turbidimetric Tests: Turbidimetric LAL Test, Turbidimetric Factor C Assay

4) By Gel Clot Tests: Gel Clot LAL Test

5) By MAT Test (Monocyte Activation Test): Direct MAT, Indirect MAT

6) By Rabbit Pyrogen Test: Standard Rabbit Pyrogen Test

7) By Recombinant Factor C (rFC) Assay: RFC Assay For Endotoxin Detection

Which Trends Are Impacting The Progress Of The Endotoxin Testing Market?

Leading companies in the endotoxin testing market are prioritizing the development of advanced solutions, such as integrated absorbance microplate readers, to enhance testing precision, optimize laboratory workflows, and reinforce adherence to data integrity standards. Advanced absorbance readers used in endotoxin testing refer to instruments engineered to seamlessly integrate with specialized assay software, support validated workflows, and consistently produce results that align with industry benchmarks. For instance, in August 2023, Lonza Group AG, a pharmaceutical, biotechnology, and nutrition manufacturing company based in Switzerland, introduced the Nebula Absorbance Reader. This next-generation microplate reader was designed to simplify endotoxin and pyrogen testing. Fully integrated with Lonza’s latest WinKQCL software, the system facilitates compliance with data integrity, reduces validation burden, and minimizes training needs by allowing existing WinKQCL users to operate the new reader without requiring additional software training. Conceived as a technologically advanced replacement for the discontinued ELx808 absorbance reader, the Nebula platform delivers comparable performance and is specifically optimized for Lonza’s absorbance-based endotoxin assays, including the PYROGENT 5000 Turbidimetric and Kinetic-QCL Chromogenic Endotoxin Assays.

Who Are The Companies Participating In The Endotoxin Testing Market?

Major companies operating in the endotoxin testing market are Thermo Fisher Scientific Inc., Merck KGaA, bioMérieux SA., Eurofins Scientific SE, Lonza Group Ltd., WuXi AppTec Co. Ltd., Bio-Rad Laboratories Inc., Maravai LifeSciences Holdings Inc., Cambrex Corporation, GenScript Biotech Corporation, Charles River Laboratories International Inc., Nelson Laboratories LLC, Lifecore Biomedical Inc., Stellar Biotechnologies Inc., Biovision Inc., Associates of Cape Cod Inc., FUJIFILM Wako Pure Chemical Corporation, InvivoGen Inc., Tebu-bio Nv., MatTek Corporation, Microcoat Biotechnologie GmbH, Accelagen Inc., BioAssay Systems LLC, BioThema AB, Hycult Biotech Inc., Pacific Biolabs Inc., Xiamen Bioendo Technology Co. Ltd., Zhanjiang A&C Biological Ltd., Accugen Laboratories Inc.

Get The Full Endotoxin Testing Market Report:

https://www.thebusinessresearchcompany.com/report/endotoxin-testing-global-market-report

Which Region Holds The Highest Market Share In The Endotoxin Testing Market?

North America was the largest region in the endotoxin testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endotoxin testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Endotoxin Testing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/endotoxin-testing-global-market-report

Browse Through More Reports Similar to the Global Endotoxin Testing Market 2026, By The Business Research Company

In Vitro Toxicology Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/in-vitro-toxicology-testing-global-market-report

Immunotoxin Market Report 2026

https://www.thebusinessresearchcompany.com/report/immunotoxin-global-market-report

Genetic Toxicology Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/genetic-toxicology-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795